Linked Life Data

16223958

Source:http://linkedlifedata.com/resource/pubmed/id/16223958

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2005-12-29
pubmed:abstractText
Nonsteroidal anti-inflammatory drugs (NSAIDs) exert anti-inflammatory, analgesic, and antipyretic activities and suppress prostaglandin synthesis by inhibiting cyclooxygenase, an enzyme that catalyzes the formation of prostaglandin precursors from arachidonic acid. Epidemiological observations indicate that the long-term treatment of patients suffering from rheumatoid arthritis with NSAIDs results in reduced risk and delayed onset of Alzheimer's disease. In this study, we investigated the therapeutic potential for Alzheimer's disease of mefenamic acid, a commonly used NSAID that is a cyclooxygenase-1 and 2 inhibitor with only moderate anti-inflammatory properties. We found that mefenamic acid attenuates the neurotoxicities induced by amyloid beta peptide (Abeta)(1-42) treatment and the expression of a Swedish double mutation (KM595/596NL) of amyloid precursor protein (Swe-APP) or the C-terminal fragments of APP (APP-CTs) in neuronal cells. We also show that mefenamic acid decreases the production of the free radical nitric oxide and reduces cytochrome c release from mitochondria induced by Abeta(1-42), Swe-APP, or APP-CTs in neuronal cells. In addition, mefenamic acid up-regulates expression of the antiapoptotic protein Bcl-X(L). Moreover, our study demonstrates for the first time that mefenamic acid improves learning and memory impairment in an Abeta(1-42)-infused Alzheimer's disease rat model. Taking these in vitro and in vivo results together, our study suggests that mefenamic acid could be used as a therapeutic agent in Alzheimer's disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0026-895X
pubmed:author
pubmed:issnType
Print
pubmed:volume
69
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
76-84
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:16223958-Alzheimer Disease, pubmed-meshheading:16223958-Amyloid beta-Peptides, pubmed-meshheading:16223958-Animals, pubmed-meshheading:16223958-Anti-Inflammatory Agents, Non-Steroidal, pubmed-meshheading:16223958-Caspase 3, pubmed-meshheading:16223958-Caspases, pubmed-meshheading:16223958-Cell Differentiation, pubmed-meshheading:16223958-Cognition Disorders, pubmed-meshheading:16223958-Enzyme Activation, pubmed-meshheading:16223958-Male, pubmed-meshheading:16223958-Mefenamic Acid, pubmed-meshheading:16223958-Membrane Potentials, pubmed-meshheading:16223958-Mitochondria, pubmed-meshheading:16223958-Nerve Growth Factor, pubmed-meshheading:16223958-Neuroprotective Agents, pubmed-meshheading:16223958-PC12 Cells, pubmed-meshheading:16223958-Peptide Fragments, pubmed-meshheading:16223958-Rats, pubmed-meshheading:16223958-Rats, Wistar, pubmed-meshheading:16223958-Reactive Oxygen Species, pubmed-meshheading:16223958-Transfection
pubmed:year
2006
pubmed:articleTitle
Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models.
pubmed:affiliation
Department of Pharmacology, College of Medicine National Creative Research Initiative Center for Alzheimer's Dementia Seoul National University Seoul, 110-799, South Korea.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't